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Abstract
Background—Research comparing the survival of children with familial dilated cardiomyopathy 
(FDCM) to that of children with idiopathic dilated cardiomyopathy (IDCM) has produced 
conflicting results.
Methods and Results—We analyzed data from children with FDCM or IDCM using the 
National Heart, Lung, and Blood Institute-funded Pediatric Cardiomyopathy Registry. Compared 
to children with IDCM (n=647), children with FDCM (n=223) were older (mean 6.2 vs. 4.5 years, 
P <0.001), less often had heart failure (64% vs. 78%, P <0.001), had less-depressed mean left 
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ventricular (LV) fractional shortening z-scores (−7.85 ± 3.98 vs. −9.06 ± 3.89, P <0.001) and 
lower end-diastolic dimension z-scores (4.12 ± 2.61 vs. 4.91 ± 2.57, P <0.001) at diagnosis. The 
cumulative incidence of death was lower for patients with FDCM compared with IDCM (P=0.04; 
hazard ratio 0.64, P=0.06) but no difference in risk of transplant or the combined death or 
transplant outcome. There was no difference in the proportion of children with echocardiographic 
normalization at three years of follow-up (FDCM, 30% vs. IDCM, 26%; P=0.33). Multivariable 
analysis showed no difference in outcomes between FDCM and IDCM but for both groups older 
age, congestive heart failure (CHF) and increased LV end-systolic dimension z-score at diagnosis 
were independently associated with an increased risk of death or heart transplantation (all Ps 
<0.001).
Conclusions—There was no survival difference between FDCM and IDCM after adjustment for 
other factors. Older age, CHF, and greater LV dilation at diagnosis were independently associated 
with increased risk of the combined endpoint of death or transplantation.
Clinical Trial Registration—https://clinicaltrials.gov; NCT00005391
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Reports from the National Heart, Lung, and Blood Institute-funded Pediatric 
Cardiomyopathy Registry (PCMR) have shown that dilated cardiomyopathy (DCM) is 
diagnosed in 0.57 of every 100,000 children per year in the US and has a 5-year risk of death 
or heart transplantation of 46%.1,2 These results are consistent with those from pediatric 
cohort studies in Australia and Finland.3,4
In adults, DCM occurs mainly secondary to coronary artery disease.5 In children, DCM has 
a wide spectrum of causes: myocarditis, neuromuscular disease, inborn errors of 
metabolism, malformation syndromes, FDCM and secondary forms caused by 
environmental or therapeutic exposures, endocrine disease, although nearly 70% of cases are 
categorized as idiopathic.1
Over the past 30 years, outcomes of children with cardiomyopathy have improved little and 
only by the introduction of heart transplantation.6 In a previous study, Towbin et al. found 
that the 5-year survival of children with DCM varied depending on cause,1 with the best 
clinical outcomes observed in children with FDCM (94%), and the worst in children with 
neuromuscular disorders (57%). Survival of children with idiopathic disease and 
malformation syndromes was intermediate (76% for both).1 Unfortunately, the same study 
found that a cause of DCM was identified in only 34% of children, although comprehensive 
etiologic testing was not always conducted.1,7 Another report from the PCMR, using 
competing risks analysis, showed that children who had FDCM at the time of diagnosis had 
a lower death rate but a similar transplant rate at 5 years after diagnosis when compared to 
IDCM.8
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Since previous studies have suggested that outcomes in children with DCM are related to the 
etiology of DCM, improving the ability to identify the underlying etiology of the disease 
could improve risk estimates and treatment strategies. Knowing the underlying etiology of 
DCM is also a prerequisite for risk assessment for family members. Therefore, we undertook 
a new PCMR analysis comparing children with FDCM to children with IDCM with a 
documented negative family history.
We hypothesized that transplant-free survival (absence of death and/or heart transplantation) 
at time of last follow-up would be better in children with FDCM than in those with IDCM. 
Using data from the PCMR, we also identified and compared the predictors of the combined 
endpoint of death or transplant of children with FDCM to those with IDCM.
Methods
The PCMR is a cooperative effort of nearly 100 centers in the United States and Canada that 
enrolled children with primary cardiomyopathy between January 1990 and February 2009. 
The PCMR design and implementation are described in detail elsewhere.2 The study was 
approved by an institutional review committee and the subjects gave informed consent.
Briefly, children less than 18 years old, newly diagnosed with cardiomyopathy at 
participating centers, were eligible for inclusion. Children were ineligible if they had a 
specific secondary cause of DCM, such as pulmonary parenchymal or vascular disease, 
endocrine disease, rheumatic disease, immunologic disease, cardiotoxic exposures, or a 
congenital cardiovascular malformation that occurred independently of a malformation 
syndrome. All participating centers obtained Institutional Review Board approval to enroll 
patients in the registry.
Demographics, family history, vital and transplant status, and clinical data relevant to 
cardiomyopathy, including echocardiographic measurements, were collected at diagnosis 
and annually thereafter.
For the present analysis, the diagnosis of DCM (defined as a DCM phenotype without a 
mixed phenotype such as DCM with hypertrophic or restrictive features or coexisting left 
ventricular non-compaction) was determined using strict echocardiographic criteria, 
including evidence of left ventricular (LV) dilation and systolic dysfunction; semi-
quantitative echocardiographic patterns of DCM; a confirmed DCM diagnosis by autopsy or 
endomyocardial biopsy; or other compelling clinical evidence of DCM.1 Familial DCM was 
defined as a patient with a clinical diagnosis of FDCM documented in the medical record by 
the treating cardiologist at the last known follow-up and/or at least one or more affected 
family members (regardless of age) noted in the medical record. This report is based on 
analysis of the results from the PCMR database as of January 14, 2013.
Study Variables
Demographic variables included age, sex, and race/ethnicity. Congestive heart failure (CHF) 
at diagnosis, as indicated in the medical record and a family history of sudden death were 
also included in analyses. Echocardiographic measurements, including LV end-diastolic 
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dimension (LVEDD) and end-systolic dimension (LVESD), LV end-diastolic posterior wall 
thickness, end-diastolic septal thickness, and LV mass were expressed as z-scores relative to 
body surface area in normal children;9 LV fractional shortening (LVFS) and LV ejection 
fraction (LVEF) were expressed as age-adjusted z-scores.10 Data on the presence of atrial 
enlargement (left, right, or both), and LVEF were available for less than half of children so 
were not analyzed further.
Statistical Methods
A Fisher exact test was used to compare the frequencies of categorical variables; Student’s t 
test (for variables with normal distributions) and the Wilcoxon rank sum test (for variables 
with other continuous distributions) were also used to evaluate differences by the presence 
or absence of FDCM.
The Kaplan-Meier method was used to estimate the incidence of the composite endpoint of 
the earliest occurring of pre-transplant death and cardiac transplant. The two components of 
the composite, pre-transplant mortality and transplant, were analyzed using cumulative 
incidence functions (CIFs), as death is a competing risk to the occurrence of transplant, with 
use of Gray’s test11 for hypothesis testing. Regression modeling to compare the incidence of 
pre-transplant death and the incidence of transplant between the FDCM vs. IDCM groups 
was conducted using the subdistribution hazard model methodology of Fine and Gray.12 
Similarly, the echocardiographic outcomes were analyzed in a competing risks framework 
with the methodology described above13. The component outcomes were echocardiographic 
normalization, pre-transplant death/transplant composite and persistently abnormal 
echocardiogram. Echocardiographic normalization was defined as having both LVEDD <2 
SD above normal for body surface area (LVEDD z-score < 2) and LVFS or LVEF <2 SD 
below normal for age (LVFS or LVEF z-score > −2).
Cox proportional hazards regression modeling was used to assess FDCM vs. IDCM 
differences in the composite outcome of death/transplant, and to identify the factors that 
were univariately associated with the composite endpoint. To determine whether predictors 
of death/transplant differed for FDCM and IDCM, each covariate was tested for interaction. 
Multivariable modeling was used to identify independent predictors of death/transplant. The 
multivariable model selection procedure included all variables with a univariate P-value less 
than 0.20, with the exception of medications at diagnosis, left or right atrial enlargement and 
ejection fraction because of the large number of missing values for these variables. The 
procedure to construct appropriate covariate-adjusted models included all variables with a 
FDCM vs. IDCM univariate P-value less than 0.10. However, LVEDD rather than LV ESD 
was utilized for final models due to missing data in the latter.
Alpha was set at 0.05, and all tests were two-tailed. Data were analyzed with the Statistical 
Analysis System statistical software program, version 9.3 (SAS Institute, Cary, North 
Carolina), the free software package R “cmprsk” and S-PLUS version 6.1 (Insightful 
Corporation, Seattle, Washington).
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Results
Demographic and Clinical Characteristics
As of January 2013, 1834 children with DCM were enrolled in the PCMR. Of these, 223 
were identified as having FDCM and 647 as having IDCM as of their last follow-up visit. 
We excluded 964 patients: 357 whose family history was unknown; 153 with a diagnosis of 
IDCM who were found to have another etiology (myocarditis, inborn errors of metabolism, 
malformation syndromes, neuromuscular disorders) at follow-up; and 454 children in whom 
a specific etiology (other than FDCM) was identified at clinical presentation. The median 
follow-up time of patients who did not reach an endpoint of death or transplantation (non-
transplanted survivors) was 3.7 years (interquartile range [IQR]: 1.0 to 6.9 years) for the 
FDCM group and 2.1 years (IQR: 0.6 to 5.1) for the IDCM group. The median follow-up 
time for the entire cohort across both groups was 2.4years (IQR: 0.8 to 5.6)
Children with FDCM were significantly older at presentation than children with IDCM 
(median, 3.3 years [IQR: 0.3 to 12.1] vs. 1.0 year [IQR: 0.3 to 9.2]), less likely to have CHF 
at diagnosis (64.1% vs. 78.2%, P < 0.001), and more likely to have a family history of 
sudden death (39.0% vs. 2.5%, P < 0.001; Table 1). Children with FDCM also had 
significantly lower mean z-scores for LVEDD (P = 0.006), and significantly higher mean z-
scores for end-diastolic septal thickness (P = 0.034), LVFS (P < 0.001), and LVEF (P = 
0.008; Table 1). Compared to children with FDCM, children with IDCM were significantly 
more likely to receive any cardiac medication at diagnosis (95.8% vs. 91.4%, P = 0.03) and 
antiarrhythmic therapy (23.5% vs. 13.7%, P = 0.02).
Outcomes
We observed 99 events in the 223 patients with FDCM (22 deaths, 77 transplants) and 296 
events in the 647 patients with IDCM (90 deaths, 206 transplants). There was a significant 
difference in the cumulative incidence of pre-transplant mortality; children with FDCM 
fared better than those with IDCM (Gray’s test P = 0.04; Fine-Gray hazard ratio for pre-
transplant death 0.64; Figure 1a). The cumulative incidence of pre-transplant death at 3 
years post-cardiomyopathy was 8.8% (95 confidence interval [CI]: 5.4% to 13.2%) and 
14.6% (95% CI: 11.8% to 17.8%) in the FDCM and IDCM groups, respectively. However, 
the hazard ratio for pre-transplant death in the FDCM vs. IDCM groups after adjustment for 
the presence of CHF at diagnosis did not differ from one (hazard ratio [HR]: 0.71, 95% CI 
0.44 to 1.13, P = 0.14; Table 2).
There was no significant difference in the cumulative incidence of transplant (P = 0.72, 
Figure 1b), nor for the distributions for time to the composite outcome of death/transplant (P 
= 0.15, Figure 2). The cumulative incidence of transplant at 3 years with pre-transplant death 
as competing risk were 34.2% (95 CI: 27.5% to 41.0%) and 36.1% (95% CI: 32.1% to 
40.3%) in the FDCM and IDCM groups, respectively (P = 0.997). In covariate-adjusted 
models for the separate outcomes of pre-transplant death and transplantation, there remained 
no difference between the FDCM and IDCM groups (Table 2).
At three years after diagnosis of cardiomyopathy, there was no difference in the proportion 
of children with echocardiographic normalization between patients with FDCM and those 
Rusconi et al. Page 5
Circ Heart Fail. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with IDCM (P = 0.33). The rates were 30% vs. 26%, respectively, at 3 years. We found no 
differences in medical therapy between the children with echo normalization and those 
without for both the IDCM and FDCM group except that children with FDCM who did not 
have echo normalization were significantly more likely to receive anticongestive therapies (P 
< 0.001).
Risk Factors for Death/Transplant
Since there were no differences in time to death or transplant between FDCM and IDCM 
groups, we combined the groups and identified univariate risk factors for the composite 
outcome of time to death or transplantation since diagnosis (Table 3). The risk of death or 
transplant was associated with older age at diagnosis (HR: 1.03, 95% CI: 1.01 to 1.05). 
Diagnosis after 1 year of age significantly increased the risk of death or transplant by nearly 
40% (HR: 1.39, 95% CI: 1.14 to 1.70). The hazard ratio for death or transplant was 3.18 
times as large for children with CHF at diagnosis as it was for those without (Table 3). For 
the subset of children with medication class data, antiarrhythmic use was associated with 
death/transplant (HR: 1.73, 95% CI: 1.22 to 2.46). We identified an interaction (P = 0.025) 
between DCM type (FDCM vs. IDCM) and only one clinical factor: LVEDD z-score. More 
abnormal dilation was a significant risk factor for both groups, but the effect was stronger 
for children with FDCM (HR: 1.24, 95% CI: 1.14 to 1.35 in FDCM vs. HR: 1.10, 95% CI: 
1.05 to 1.16 in IDCM). However, for the entire cohort the only independent predictors of 
death/transplant were those shown in the multivariable model in Table 2 (LVEDD z-score 
without an interaction; CHF; and older age at diagnosis).
Discussion
The study analyzes outcome and risk factors in patients with FDCM and DCM. The major 
finding is that the risk factors for the composite outcome of death or transplant are CHF and 
older age at diagnosis, particularly age at presentation older than 1 year increased the risk of 
death or transplant by almost 40%; dilatation of the LV (LVEDD z-score) was also a 
significant risk factor for death or transplant. In the subsets of children with medications 
data available, we found that antiarrhythmic use was associated with an increase of death or 
transplant; this finding may reflect the fact that patients were sicker although the possibility 
of a proarrhythmic effect cannot be excluded and caution should be used when starting these 
drugs. Our findings show that the etiology of cardiomyopathy, FDCM or IDCM was not a 
factor in determining the outcome; patient clinical characteristics are the major determinant.
Although there was no difference in outcome between the FDCM and IDCM groups, we 
found that children with FDCM were significantly older at the time of diagnosis, less likely 
to present with heart failure, and more likely to have a positive family history of sudden 
cardiac death than were children with IDCM. In addition, they showed less evidence of 
pathologic LV remodeling at presentation as shown by significantly less, but still abnormal, 
LV dilation, less septal thinning, and better, but still abnormal, LV function (LVFS or 
LVEF). Children with IDCM were more likely to be on cardiac medications and 
antiarrhythmic at diagnosis probably reflecting the fact that IDCM children were sicker at 
presentation as evidence that they were more likely to present with CHF.
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Of children with either FDCM or IDCM, 26% to 30% experienced echocardiographic 
normalization over time, a finding consistent with normalization rates in a previous PCMR 
analysis of all IDCM patients (regardless of family history).14
Our report represents perhaps the largest study to date in children comparing clinical 
outcomes in FDCM and IDCM. In previous studies of patients with IDCM, further 
investigation of relatives found that between 20% and 50% of index cases had FDCM.15–18 
Although these studies were mostly of adults, they all included pediatric cases of DCM. In 
our study, of the 1832 cases of pure DCM in the PCMR database, 12% of children had a 
diagnosis of FDCM at their most recent follow-up. Similarly, in the National Australian 
Childhood Cardiomyopathy Study, the prevalence of FDCM in children less than 10 years of 
age was 14.7%.3
Clear clinical or echocardiographic markers that differentiate FDCM from IDCM have been 
difficult to identify. FDCM cannot be reliably diagnosed in any individual child based solely 
on clinical (other than family history) or echocardiographic data, a finding consistent with 
other reports.15,17,19 Even an accurate family history can not necessarily identify FDCM at 
the time of diagnosis. Indeed, as illustrated by the PCMR experience, it is likely that a subset 
of the patients categorized as IDCM will be subsequently determined to have FDCM due to 
the manifestation of the disease in relatives at a later time and others may carry the same 
causative gene mutations despite the absence of a prior family history of DCM. Presently, 
the diagnosis of FDCM requires assembling a complete and accurate family history, as well 
as screening family members with echocardiography or another imaging modality. A recent 
review concluded that proper screening of family members with echocardiography or other 
assessments of LV size and function will detect FDCM in 20% to 35% of patients with 
IDCM.20 Genetic evaluation of these populations using newly available DCM genetic testing 
panels should improve identification of children with FDCM. Since most cases of IDCM are 
suspected to have a genetic etiology, evaluation of these children with clinically available 
DCM genetic testing panels is also important.
For many years, genetic testing for DCM in children has been used infrequently in clinical 
practice because of the high cost with traditional sequencing methods and the relatively low 
probability of identifying a mutation in one of the many DCM genes. However, large gene 
panels are now available as a result of the development of next-generation sequencing 
approaches which can screen a larger number of genes simultaneously at lower cost and also 
result in a higher number of positive results.20–22 Thus, incorporating genetic testing and 
genetic counseling into the care of patients with DCM is recommended.23,24 In a Australian 
prospective study of sudden cardiac death in children and young adults the authors showed
Genetic testing performed at autopsy was able to identify a likely cause of death in 27% of 
the cases of unexplained sudden cardiac death.25 Although the cost-effectiveness of genetic 
testing in DCM has not yet been evaluated, studies on the cost-effectiveness of genetic 
testing in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, 
and long QT syndrome indicate an overall benefit over screening via cardiac 
surveillance.26,27
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Strengths and Limitations of the Study
The PCMR is the largest longitudinal study of cardiomyopathy in children, including more 
than 3,500 affected children. However, the diagnosis of FDCM or evidence of affected 
family members in children with IDCM was identified only from the medical record. 
Specifically, the diagnosis of FDCM was based on a notation of FDCM in the medical 
record without any a priori PCMR requirement for data on detailed pedigrees or from 
comprehensive genetic testing (which has evolved considerably over the life of the PCMR) 
to establish a diagnosis of FDCM. It is important to note that family history is dynamic and 
needs to be revisited at each clinical encounter since children initially diagnosed as IDCM, 
may later be categorized as FDCM, given their updated family history or new genetic testing 
data. Related to this approach for identifying FDCM, it is possible that the patients in the 
FDCM group appear to have better survival than IDCM since longer follow-up allows more 
opportunity to be classified as FDCM. Furthermore, screening echocardiograms of family 
members were not available. Medication class was only available for a subset of patients. 
Almost 30% of the IDCM cases in the PCMR could not be used in the analysis as a result of 
inconclusive family histories. Determining whether or not a patient has familial disease is 
often difficult, and there is evidence that correct classification requires consistent and 
ongoing echocardiographic investigation of relatives, who may present with DCM at various 
ages.17,28 Finally, we found no statistically significant difference in the time to death/
transplant (43% vs. 51% for FDCM vs. IDCM at 3 years). This difference may be 
considered clinically significant, but we had limited statistical power due to the shorter 
follow-up time in the IDCM group.
Echocardiographic screening of relatives has shown that relying on family history alone to 
identify FDCM may not identify asymptomatic family members with cardiomyopathy or 
detect whether relatives reported to have DCM may actually have had other cardiac 
diseases.28 Because our study relied solely on the family history found in the medical record 
to make the diagnosis of FDCM, some children may have been misclassified with respect to 
final DCM category. Changes in clinical protocols addressing the acquisition and 
documentation of complete pedigrees and comprehensive family screening in this population 
over the course of this study could also have affected the percentage of children classified as 
FDCM.
Future Directions
Nearly half of our FDCM cases were not identified as such at their initial clinical 
presentation. Our findings suggest that at least the first-degree relatives of children 
presenting with DCM without a clear non-familial cause should undergo echocardiographic 
screening. Additionally, state-of-the art clinical genetic testing of the proband, and if 
positive, of other family members, should be used to more accurately make the diagnosis of 
FDCM in the affected child. Advances in clinical genetic testing for DCM, including the 
development of more comprehensive panels and cost-effective whole-genomic analysis, will 
eventually provide a more rapid and definitive diagnosis of FDCM in children.
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Conclusions
At diagnosis in both FDCM and IDCM, older age, the presence of CHF, and increased LV 
dilation are independently associated with poor outcomes. At the time of diagnosis, children 
eventually categorized as FDCM appear to be at an earlier stage of the disease with less LV 
remodeling, and a lower prevalence of heart failure, when compared to children with IDCM.
In summary, recognition of FDCM is important regarding the implications for screening 
other family members, but not for the management of the affected individual, since the 
outcomes are related to patient factors, not whether the child has FDCM or IDCM.
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Clinical Perspective
Our report represents perhaps the largest study to date comparing clinical outcomes in 
Familial Dilated Cardiomyopathy (FDCM) and Idiopathic Dilated Cardiomyopathy 
(IDCM) in children. We found that children with FDCM were significantly older at the 
time of diagnosis, less likely to present with heart failure, and more likely to have a 
positive family history of sudden cardiac death than were children with IDCM. We found 
no covariate-adjusted difference between the FDCM and IDCM groups in time to death, 
transplant, or the combined endpoint of death/transplantation. They also had less 
evidence of pathologic LV remodeling at presentation as shown by significantly less, but 
still highly abnormal, LV dilation, less septal thinning, and better, but still highly 
abnormal, LV function (LVFS or LVEF). Our findings suggest that at least the first-
degree relatives of children presenting with DCM without a clear non-familial cause 
should undergo echocardiographic screening. Additionally, state-of-the art clinical 
genetic testing of both the proband, and if positive, of other family members, should be 
used to more accurately make the diagnosis of FDCM in the affected child. Advances in 
clinical genetic testing for DCM, including the development of more comprehensive 
genetic testing panels and cost-effective whole-genomic analysis, will eventually provide 
a more rapid and definitive diagnosis of FDCM in children. Since most cases of IDCM 
are suspected to have a genetic etiology evaluation of these children with clinical 
available DCM genetic testing panels is also important. In summary, recognition of 
FDCM is important regarding the implications for screening other family members, but 
not for the management of the affected individual, since the outcomes are related to 
patient factors, not whether the child has FDCM or IDCM.
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Figure 1. 
Competing outcomes analysis showing estimated proportion of patients in three mutually 
exclusive groups at all times after diagnosis (alive, transplanted, and died without transplant) 
in a) familial dilated cardiomyopathy and b) idiopathic dilated cardiomyopathy. Summation 
of proportions equals 1 at all time points. CM = cardiomyopathy.
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Figure 2. 
Kaplan-Meier curve comparing time to death and transplantation between children with 
familial dilated cardiomyopathy (FDCM) and idiopathic cardiomyopathy without a family 
history of cardiomyopathy (IDCM). Log-rank P = 0.15; 395 events.
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Table 1
Characteristics of Children with Familial Dilated Cardiomyopathy or Idiopathic Dilated Cardiomyopathy.
Characteristic Overall FDCM IDCM P Value*
N† 870 223 647
Age at diagnosis
 Mean (SD), years 4.9 (5.9) 6.2 (6.4) 4.5 (5.8) 0.001
 Median (IQR), years 1.2 (0.3–10.3) 3.3 (0.3–12.1) 1.0 (0.3–9.2) 0.04
Age < 1 year at diagnosis, % 47.4 42.2 49.2 0.07
Male, % 50.6 54.7 49.1 0.16
Race/ethnicity, % 0.06
 White 54.2 60.1 52.2
 Black 21.2 16.1 23.0
 Hispanic 17.3 15.1 18.0
 Other 7.3 8.7 6.8
Congestive heart failure at diagnosis, % 74.6 64.1 78.2 < 0.001
Family history of sudden death, % (total n) 10.5 (727) 39.0 (159) 2.5 (568) < 0.001
Left ventricular echocardiographic z-scores, mean (SD)
 End-diastolic dimension (total n = 699, 175, 524) 4.71 (2.60) 4.12 (2.61) 4.91 (2.57) < 0.001
 End-systolic dimension (total n = 614, 160, 454) 6.35 (3.00) 5.79 (2.89) 6.55 (3.01) 0.006
 Fractional shortening (total n = 713, 183, 530) −8.74 (3.95) −7.85 (3.98) −9.06 (3.89) < 0.001
 End-diastolic posterior wall thickness (total n = 553, 145, 408) −0.60 (2.58) −0.63 (2.66) −0.59 (2.56) 0.86
 End-diastolic septal thickness (total n = 515, 126, 389) −0.98 (1.92) −0.67 (1.99) −1.09 (1.88) 0.03
 Mass (total n = 545, 143, 402) 2.49 (2.78) 2.32 (3.08) 2.55 (2.67) 0.43
Medications at diagnosis (n)
 Any cardiac medication 94.7% (786) 91.4% (198) 95.8% (588) 0.03
 Anticongestive therapy¶ 86% (843) 82.2% (213) 87.3% (630) 0.07
 Antiarrhythmic therapy 20.6% (462) 13.7% (139) 23.5% (323) 0.02
 ACE inhibitor 62.7% (461) 60.9% (138) 63.5% (323) 0.60
 Beta blocker 13.2% (461) 15.1% (139) 12.4% (322) 0.46
 Carnitine 1.5% (461) 0.7% (139) 1.9% (322) 0.68
FDCM, familial dilated cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; IQR, interquartile range.
*P values compare the differences between FDCM and IDCM.
†Sample size is smaller than the total stated for selected variables (family history; LV mass).
¶Anticongestive therapy is defined as digoxin and/or diuretics
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Table 3
Univariate Analysis of Predictors of the Composite Outcome (Death or Heart Transplantation) in Children 
with Familial Dilated Cardiomyopathy (FDCM) or Idiopathic DCM (IDCM).
Characteristics n/% Hazard Ratio (95% CI) P Value
Type of dilated cardiomyopathy 870 0.15
 Familial dilated cardiomyopathy 223 Reference
 Idiopathic dilated cardiomyopathy 647 1.18 (0.94–1.49)
Age at diagnosis, years 870 1.03 (1.01–1.05) < 0.001
Age ≥ 1 year at diagnosis 52.6% (458/870) 1.39 (1.14–1.70) 0.001
Male 50.6% (440/870) 1.12 (0.92–1.36) 0.28
Race/ethnicity 852 0.03
 White 462 Reference
 Black 181 1.15 (0.90–1.46)
 Hispanic 147 0.71 (0.52–0.95)
 Other 62 0.82 (0.53–1.25)
CHF present at diagnosis 74.6% (648/869) 3.18 (2.36–4.29) < 0.001
Family history of sudden death −10.5% (76/727) 1.01 (0.72–1.40) 0.98
Echocardiographic z-scores
 LV end-diastolic dimension 699 1.14 (1.09–1.19) < 0.001
 LV end-systolic dimension 614 1.16 (1.10–1.21) < 0.001
 LV fractional shortening 713 0.91 (0.87–0.94) < 0.001
 LV end-diastolic posterior wall thickness 553 1.04 (0.99–1.09) 0.15
 End-diastolic septal thickness 515 1.02 (0.95–1.09) 0.67
 LV mass 545 1.09 (1.05–1.13) < 0.001
CHF, congestive heart failure; CI, confidence interval; LV, left ventricular.
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